EBS (Emergent Corp) Net earnings per share (EPS TTM)

Emergent BioSolutions Inc (EBS) - corporate logo

Emergent BioSolutions (EBS) operations rely on US government biodefense contracts. The share price history on GURU.Markets reflects EPS dynamics, which stand at -458.40. Rising demand for smallpox vaccines and Narcan, coupled with debt restructuring, is driving profitability. Simultaneously, Emergent BioSolutions (EBS) is optimizing its workforce, striving to retain key manufacturing experts during a period of personnel transformation and targeted hiring.

EBS Emergent Corp: Net earnings per share (EPS TTM) in the range 02/11/2024 - 11/13/2026

Emergent Corp - analytical breakdowns and key metrics (EBS)

- current price and projected stock value:
Price Performance Chart emergentbiosolutions.com|EBS - Consensus Target
- business market valuation indicators:
Market Capitalization Emergent BioSolutions Inc|EBS - Total Company Value
- shareholders' equity book value data:
Net Assets per Share Emergent BioSolutions|EBS - Book Capitalization|Market-to-Book Ratio emergentbiosolutions.com|EBS - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Emergent BioSolutions|EBS - Long-Term Debt to Capital|Current Liabilities to Capital Emergent Bio|EBS - Company Debts|Debt to Net Assets Ratio Emergent BioSolutions Inc|EBS - Company Long-Term Debts|Short-Term Indebtedness Emergent BioSolutions|Immediate Liquidity emergentbiosolutions.com
- business earnings and investment ratios data:
EBS - Company Net Income|Net Profit Forecast Emergent BioSolutions|EBS - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Emergent BioSolutions Inc|EBS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Emergent BioSolutions Inc|EBS - Operating profit EBITDA|Earnings per share for the last twelve months Emergent BioSolutions|EBS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months emergentbiosolutions.com|EBS - Earnings per share growth in current year|Expected net earnings per share growth next year Emergent BioSolutions
- sales and revenue indicators:
EBS - Company Revenue|Company Future Sales emergentbiosolutions.com|EBS - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Emergent BioSolutions Inc
Initial company analysis:emergentbiosolutions.com EBS
Manufactured product of Emergent BioSolutions Inc.

The monopoly position of Emergent BioSolutions (EBS) in the US biodefense sector guarantees stable demand for vaccines regardless of market conditions. This pricing power translates directly into net profit per share dynamics. This metric measures the rolling annual rate of change in EPS, allowing for an assessment of real business efficiency without market noise. Analyzing the annual growth of EPS TTM helps investors determine the company's true growth momentum relative to sector peers.

Competitor analysis for Emergent BioSolutions

Earnings per share for the trailing year GILD (gilead.com)|CDTX (Cidara Therapeutics Corp) - Net earnings per share for the last 12 months|Novavax Inc (NVAX) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months CureVac Corp|Valneva Vaccines (VALN) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) VIR|SIGA - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Atea Pharmaceuticals, Inc. AVIR|IVVD - Net earnings per share for the last 12 months|Enanta - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Inovio Pharma|HilleVax, Inc. (HLVX) - Earnings per share for the last twelve months|kalaristx.com - Earnings per share for the trailing year|DYAI (Dyadic International Inc) - Net earnings per share (EPS TTM)|NNVC - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) TLPH|COCP - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Traws Pharma TRAW|DWTX: Earnings per share for the last 12 months|QLGN: Net earnings per share for the last 12 months|AlloVir, Inc. - Earnings per share for the last four quarters|VBIV (vbivaccines.com) - Net earnings per share for the last 12 months|Virios Therapeutics, Inc. - Earnings per share for the trailing year|VXRT (Vaxart Inc.) - Net earnings per share (EPS TTM)